Assessment of Circulating Blood Volume with Fluid Administration Targeting Euvolemia or Hypervolemia

Aaron M. Joffe, Nita Khandelwal, Matthew R. Hallman, Miriam Treggiari

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The occurrence of hypovolemia in the setting of cerebral vasospasm reportedly increases the risk for delayed ischemic neurologic deficits. Few studies have objectively assessed blood volume (BV) in response to fluid administration targeting normovolemia (NV) or hypervolemia (HV) and none have done so with crystalloids alone. The primary purpose was to evaluate the BV of patients with SAH receiving crystalloid fluid administration targeting NV or HV. Methods: The University of Washington IRB approved the study. Prospectively collected data was obtained from patients enrolled in a clinical trial and a concurrent group of patients who received IV fluids during the ICU stay. We defined a normovolemia (NV) and hypervolemia (HV) group based on the cumulative amount of IV fluid administered in mL/kg from ICU admission to day 5; ≥30–60 mL/kg/day (NV) and ≥60 mL/kg/day (HV), respectively. In a subgroup of patients, BV was measured on day 5 post ictus using iodinated 131I-labeled albumin injection and the BVA-100 (Daxor Corp, New York, NY). Differences between the NV and HV groups were compared using Student’s t-test with assumption for unequal variance. Results: Twenty patients in the NV and 19 in the HV groups were included. The HV group received more fluid and had a higher fluid balance than the NV group. The subgroup of patients in whom BV was measured on day 5 (n = 19) was not different from the remainder of the cohort with respect to the total amount of administered fluid and net cumulative fluid balance by day 5. BV was not different between the two groups and varied widely. Conclusions: Routinely targeting prophylactic HV using crystalloids does not result in a higher circulating BV compared to targeting NV, but the possibility of clinically unrecognized hypovolemia remains.

Original languageEnglish (US)
Pages (from-to)82-88
Number of pages7
JournalNeurocritical Care
Volume22
Issue number1
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Blood Volume
Hypovolemia
Water-Electrolyte Balance
Intracranial Vasospasm
Research Ethics Committees
Neurologic Manifestations
Albumins
Clinical Trials
Students
Injections
crystalloid solutions

Keywords

  • Blood volume
  • Daily weight
  • Fluid balance
  • Human
  • Hypervolemia
  • Neurologic injury
  • Normovolemia

ASJC Scopus subject areas

  • Clinical Neurology
  • Critical Care and Intensive Care Medicine

Cite this

Assessment of Circulating Blood Volume with Fluid Administration Targeting Euvolemia or Hypervolemia. / Joffe, Aaron M.; Khandelwal, Nita; Hallman, Matthew R.; Treggiari, Miriam.

In: Neurocritical Care, Vol. 22, No. 1, 2014, p. 82-88.

Research output: Contribution to journalArticle

Joffe, Aaron M. ; Khandelwal, Nita ; Hallman, Matthew R. ; Treggiari, Miriam. / Assessment of Circulating Blood Volume with Fluid Administration Targeting Euvolemia or Hypervolemia. In: Neurocritical Care. 2014 ; Vol. 22, No. 1. pp. 82-88.
@article{c619c6fd57b742bdb44967ee2043d9fc,
title = "Assessment of Circulating Blood Volume with Fluid Administration Targeting Euvolemia or Hypervolemia",
abstract = "Background: The occurrence of hypovolemia in the setting of cerebral vasospasm reportedly increases the risk for delayed ischemic neurologic deficits. Few studies have objectively assessed blood volume (BV) in response to fluid administration targeting normovolemia (NV) or hypervolemia (HV) and none have done so with crystalloids alone. The primary purpose was to evaluate the BV of patients with SAH receiving crystalloid fluid administration targeting NV or HV. Methods: The University of Washington IRB approved the study. Prospectively collected data was obtained from patients enrolled in a clinical trial and a concurrent group of patients who received IV fluids during the ICU stay. We defined a normovolemia (NV) and hypervolemia (HV) group based on the cumulative amount of IV fluid administered in mL/kg from ICU admission to day 5; ≥30–60 mL/kg/day (NV) and ≥60 mL/kg/day (HV), respectively. In a subgroup of patients, BV was measured on day 5 post ictus using iodinated 131I-labeled albumin injection and the BVA-100 (Daxor Corp, New York, NY). Differences between the NV and HV groups were compared using Student’s t-test with assumption for unequal variance. Results: Twenty patients in the NV and 19 in the HV groups were included. The HV group received more fluid and had a higher fluid balance than the NV group. The subgroup of patients in whom BV was measured on day 5 (n = 19) was not different from the remainder of the cohort with respect to the total amount of administered fluid and net cumulative fluid balance by day 5. BV was not different between the two groups and varied widely. Conclusions: Routinely targeting prophylactic HV using crystalloids does not result in a higher circulating BV compared to targeting NV, but the possibility of clinically unrecognized hypovolemia remains.",
keywords = "Blood volume, Daily weight, Fluid balance, Human, Hypervolemia, Neurologic injury, Normovolemia",
author = "Joffe, {Aaron M.} and Nita Khandelwal and Hallman, {Matthew R.} and Miriam Treggiari",
year = "2014",
doi = "10.1007/s12028-014-9993-8",
language = "English (US)",
volume = "22",
pages = "82--88",
journal = "Neurocritical Care",
issn = "1541-6933",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Assessment of Circulating Blood Volume with Fluid Administration Targeting Euvolemia or Hypervolemia

AU - Joffe, Aaron M.

AU - Khandelwal, Nita

AU - Hallman, Matthew R.

AU - Treggiari, Miriam

PY - 2014

Y1 - 2014

N2 - Background: The occurrence of hypovolemia in the setting of cerebral vasospasm reportedly increases the risk for delayed ischemic neurologic deficits. Few studies have objectively assessed blood volume (BV) in response to fluid administration targeting normovolemia (NV) or hypervolemia (HV) and none have done so with crystalloids alone. The primary purpose was to evaluate the BV of patients with SAH receiving crystalloid fluid administration targeting NV or HV. Methods: The University of Washington IRB approved the study. Prospectively collected data was obtained from patients enrolled in a clinical trial and a concurrent group of patients who received IV fluids during the ICU stay. We defined a normovolemia (NV) and hypervolemia (HV) group based on the cumulative amount of IV fluid administered in mL/kg from ICU admission to day 5; ≥30–60 mL/kg/day (NV) and ≥60 mL/kg/day (HV), respectively. In a subgroup of patients, BV was measured on day 5 post ictus using iodinated 131I-labeled albumin injection and the BVA-100 (Daxor Corp, New York, NY). Differences between the NV and HV groups were compared using Student’s t-test with assumption for unequal variance. Results: Twenty patients in the NV and 19 in the HV groups were included. The HV group received more fluid and had a higher fluid balance than the NV group. The subgroup of patients in whom BV was measured on day 5 (n = 19) was not different from the remainder of the cohort with respect to the total amount of administered fluid and net cumulative fluid balance by day 5. BV was not different between the two groups and varied widely. Conclusions: Routinely targeting prophylactic HV using crystalloids does not result in a higher circulating BV compared to targeting NV, but the possibility of clinically unrecognized hypovolemia remains.

AB - Background: The occurrence of hypovolemia in the setting of cerebral vasospasm reportedly increases the risk for delayed ischemic neurologic deficits. Few studies have objectively assessed blood volume (BV) in response to fluid administration targeting normovolemia (NV) or hypervolemia (HV) and none have done so with crystalloids alone. The primary purpose was to evaluate the BV of patients with SAH receiving crystalloid fluid administration targeting NV or HV. Methods: The University of Washington IRB approved the study. Prospectively collected data was obtained from patients enrolled in a clinical trial and a concurrent group of patients who received IV fluids during the ICU stay. We defined a normovolemia (NV) and hypervolemia (HV) group based on the cumulative amount of IV fluid administered in mL/kg from ICU admission to day 5; ≥30–60 mL/kg/day (NV) and ≥60 mL/kg/day (HV), respectively. In a subgroup of patients, BV was measured on day 5 post ictus using iodinated 131I-labeled albumin injection and the BVA-100 (Daxor Corp, New York, NY). Differences between the NV and HV groups were compared using Student’s t-test with assumption for unequal variance. Results: Twenty patients in the NV and 19 in the HV groups were included. The HV group received more fluid and had a higher fluid balance than the NV group. The subgroup of patients in whom BV was measured on day 5 (n = 19) was not different from the remainder of the cohort with respect to the total amount of administered fluid and net cumulative fluid balance by day 5. BV was not different between the two groups and varied widely. Conclusions: Routinely targeting prophylactic HV using crystalloids does not result in a higher circulating BV compared to targeting NV, but the possibility of clinically unrecognized hypovolemia remains.

KW - Blood volume

KW - Daily weight

KW - Fluid balance

KW - Human

KW - Hypervolemia

KW - Neurologic injury

KW - Normovolemia

UR - http://www.scopus.com/inward/record.url?scp=84921931415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921931415&partnerID=8YFLogxK

U2 - 10.1007/s12028-014-9993-8

DO - 10.1007/s12028-014-9993-8

M3 - Article

VL - 22

SP - 82

EP - 88

JO - Neurocritical Care

JF - Neurocritical Care

SN - 1541-6933

IS - 1

ER -